DE60126591D1 - In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB - Google Patents

In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB

Info

Publication number
DE60126591D1
DE60126591D1 DE60126591T DE60126591T DE60126591D1 DE 60126591 D1 DE60126591 D1 DE 60126591D1 DE 60126591 T DE60126591 T DE 60126591T DE 60126591 T DE60126591 T DE 60126591T DE 60126591 D1 DE60126591 D1 DE 60126591D1
Authority
DE
Germany
Prior art keywords
astaxanthin
man
animal
chemokines
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60126591T
Other languages
German (de)
English (en)
Inventor
Tove Andersson
Sven Pettersson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astareal AB
Original Assignee
Astacarotene AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astacarotene AB filed Critical Astacarotene AB
Application granted granted Critical
Publication of DE60126591D1 publication Critical patent/DE60126591D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
DE60126591T 2000-03-27 2001-03-21 In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB Expired - Fee Related DE60126591D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0001071A SE0001071D0 (sv) 2000-03-27 2000-03-27 Method of inhibiting the expression of inflammatory cytokines and chemokines
PCT/SE2001/000600 WO2001072296A1 (en) 2000-03-27 2001-03-21 Method of inhibiting the expression of inflammatory cytokines and chemokines

Publications (1)

Publication Number Publication Date
DE60126591D1 true DE60126591D1 (de) 2007-03-29

Family

ID=20279020

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60126591T Expired - Fee Related DE60126591D1 (de) 2000-03-27 2001-03-21 In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB

Country Status (8)

Country Link
EP (1) EP1267857B1 (enExample)
JP (1) JP2003528139A (enExample)
AT (1) ATE353639T1 (enExample)
AU (1) AU2001242965A1 (enExample)
CA (1) CA2405479C (enExample)
DE (1) DE60126591D1 (enExample)
SE (1) SE0001071D0 (enExample)
WO (1) WO2001072296A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002349784A1 (en) * 2001-12-03 2003-06-17 Asahi Kasei Pharma Corporation Nf-kappab activating genes
EP2653157B1 (en) * 2004-02-04 2016-08-03 Fuji Chemical Industry Co., Ltd. Astaxanthin for improving muscle atrophy
JP2006008714A (ja) * 2005-03-17 2006-01-12 Yamaha Motor Co Ltd マトリックスメタロプロテイナーゼ阻害剤
JP2006008718A (ja) * 2005-06-03 2006-01-12 Yamaha Motor Co Ltd シクロオキシゲナーゼ活性阻害剤
JP2006008719A (ja) * 2005-06-23 2006-01-12 Yamaha Motor Co Ltd 血中過酸化脂質抑制剤
WO2008106606A2 (en) * 2007-02-28 2008-09-04 Cardax Pharmaceuticals, Inc. Carotenoid analogs and derivatives in the treatment of prostate cancer
US7805004B2 (en) * 2007-02-28 2010-09-28 Microsoft Corporation Radical set determination for HMM based east asian character recognition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05155736A (ja) * 1991-12-10 1993-06-22 Nakano Seiyaku Kk 化粧料
JPH0799924A (ja) * 1993-09-30 1995-04-18 Nippon Suisan Kaisha Ltd アスタキサンチンを主要成分とするファフィア色素油の安定な粉末化物及びその製造方法
JPH07300421A (ja) * 1994-04-28 1995-11-14 Itano Reitou Kk 抗炎症剤
US5527533A (en) * 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
EP0806946A2 (de) * 1995-02-03 1997-11-19 Basf Aktiengesellschaft Verwendung von carotinoiden zur herstellung von arzneimitteln zur behandlung von dermatosen
JPH09124470A (ja) * 1995-10-26 1997-05-13 Suntory Ltd 抗ストレス組成物
JPH09143063A (ja) * 1995-11-22 1997-06-03 Kose Corp 外用に適する組成物
SE522246C2 (sv) * 1997-02-27 2004-01-27 Astacarotene Ab Oralt preparat för profylaktisk och terapeutisk behandling av Helicobacter Sp. infektion
WO1998045241A2 (en) * 1997-04-04 1998-10-15 Henkel Corporation Lutein esters having high bioavailability
SE512531C2 (sv) * 1997-09-04 2000-03-27 Astacarotene Ab Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur

Also Published As

Publication number Publication date
CA2405479A1 (en) 2001-10-04
JP2003528139A (ja) 2003-09-24
ATE353639T1 (de) 2007-03-15
SE0001071D0 (sv) 2000-03-27
EP1267857A1 (en) 2003-01-02
AU2001242965A1 (en) 2001-10-08
CA2405479C (en) 2010-11-16
WO2001072296A1 (en) 2001-10-04
EP1267857B1 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
ATE269089T1 (de) Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen
TR200100610T2 (tr) Asetil L-karnitin ve alfa-lipoik asit içeren antioksidant bileşim
ES2156840T1 (es) Medicamento que contiene polisulfato de pentosano e implante para tratar la fibrosis.
SE9704870D0 (sv) New pharmaceutical formulation I
AR025247A1 (es) Composiciones de granulos de carotenos-xantofilos, estables
MY111791A (en) Aqueous gel retinoid dosage form.
EA200300081A1 (ru) Гидрогель-управляемая лекарственная форма
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
ES2194501T3 (es) Derivados de amidinas, su preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
AR003463A1 (es) Una formulacion de liberacion controlada o de liberacion retardada; su utilizacion en la fabricacion de un medicamento y un procedimiento para su preparacion.
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
BR9610480A (pt) Inibição do fator alfa de necrose tumoral
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
DE60108489D1 (de) Kombinationstherapien mit gefässschädigender aktivität
DK1167354T3 (da) Racemisk huperzin A
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
ES2029228T3 (es) Procedimiento para la produccion de un preparado retardado de ibuprofeno.
SE9802208D0 (sv) Novel compounds
WO2003000203A3 (en) Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
AU2558300A (en) Substituted stilbene compounds with vascular damaging activity
ES2165232T3 (es) Sistema terapeutico transdermico (tts) que contiene oxibutinina.
Iuvone et al. Opioids inhibit the induction of nitric oxide synthase in J774 macrophages
DE60126591D1 (de) In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB
DE60137069D1 (de) Arzneizusammensetzungen enthaltend modafinilverbindungen
ATE444739T1 (de) Polymerzusammensetzung sowie diese enthaltende darreichungsformen

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee